|
Market Closed -
Euronext Dublin
19:55:00 26/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 6.250 EUR | 0.00% |
|
-10.07% | -18.83% |
| 10-23 | Malin Corp writes off investee after US FDA drug rejection | AN |
| 08-26 | Malin swings to interim profit as finance income rises and costs fall | AN |
| Market Cap | 27.09M 30.3M 25.07M 22.7M 42.48M 2.88B 43.17M 302M 119M 1.51B 114M 111M 4.77B | P/E 2024 * |
-
| P/E 2025 | -8.37x |
|---|---|---|---|---|---|
| Enterprise Value | 14.19M 15.87M 13.13M 11.89M 22.25M 1.51B 22.62M 158M 62.51M 790M 59.58M 58.3M 2.5B | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
63.83% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 week | -10.07% | ||
| Current month | -10.71% | ||
| 1 month | -10.71% | ||
| 3 months | -11.97% | ||
| 6 months | -21.38% | ||
| Current year | -18.83% |
| 1 week | 6.25 |  | 6.95 |
| 1 month | 6.25 | | 7 |
| Current year | 6.25 | | 8.45 |
| 1 year | 6.25 | | 9.3 |
| 3 years | 3.84 | | 10.4 |
| 5 years | 3.59 | | 10.4 |
| 10 years | 1.4 | | 13.24 |
| Manager | Title | Age | Since |
|---|---|---|---|
Andrea Stafford
DFI | Director of Finance/CFO | 56 | 01/05/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
William Daniel
CHM | Chairman | 73 | 02/08/2019 |
| Director/Board Member | 67 | 16/07/2018 | |
Rudy Mareel
BRD | Director/Board Member | 63 | 16/07/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/2/26 A | Exercice | 10,307 | 0.2382% | |||
| 5/28/25 A | Exercice | Chief Executive Officer | 5,746 | 0.1328% | ||
| 4/7/25 A | Sell | Director | 11,075 | 0.2560% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -10.07% | -24.70% | +56.25% | 30.34M | |
| +0.45% | +3.13% | +54.96% | +125.16% | 1,135B | |
| +0.94% | +4.93% | +39.86% | +78.72% | 635B | |
| +0.39% | +1.44% | +25.77% | +97.48% | 505B | |
| +1.43% | +4.31% | +46.20% | +67.12% | 378B | |
| -3.21% | -2.10% | +60.72% | +33.22% | 358B | |
| -0.41% | +2.64% | +22.48% | +49.82% | 295B | |
| +0.23% | +3.66% | +2.57% | +23.69% | 266B | |
| +1.22% | +4.63% | +52.40% | +64.85% | 237B | |
| +1.70% | +3.67% | +31.21% | +102.15% | 193B | |
| Average | +0.24% | +1.50% | +31.15% | +69.85% | 400.37B | |
| Weighted average by Cap. | +0.42% | +2.85% | +41.40% | +83.61% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | - | -6.9M -7.72M -6.38M -5.78M -10.82M -734M -11M -76.82M -30.39M -384M -28.96M -28.34M -1.22B |
| Net Debt | -62.1M -69.45M -57.45M -52.02M -97.36M -6.61B -98.96M -691M -273M -3.46B -261M -255M -10.94B | -12.9M -14.43M -11.93M -10.81M -20.22M -1.37B -20.56M -144M -56.81M -718M -54.14M -52.99M -2.27B |
Employees
2
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/10/26 | €6.250 | 0.00% | 1 |
| 23/10/26 | €6.250 | -9.42% | 1,627 |
| 22/10/26 | €6.900 | -0.72% | 1,064 |
| 21/10/26 | €6.950 | 0.00% | 0 |
| 20/10/26 | €6.950 | 0.00% | 0 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.250EUR
Average target price
15.50EUR
Spread / Average Target
+148.00%
- Stock Market
- Stocks
- MLC Stock
Select your edition
All financial news and data tailored to specific country editions
